Skip to content
Screener

Arbutus Biopharma Corporation ABUS Business Segments — Revenue

Similar metrics at other companies

Adobe logo
ADBEReportable Segment — Revenue
$6.62B+12.7%
BitGo Holdings logo
BTGOReportable Segment — Revenue
$3.77B+113%
Energy Vault Holdings logo
NRGVReportable Segment — Revenue
$21.88M+156%
Nextpower Inc. logo
NXTReportable Segment — Revenue
$880.52M-4.7%
Guardant Health logo
GHReportable Segment — Revenue
$301.67M+48.3%
Paylocity logo
PCTYReportable Segment — Revenue
$444.73M+11.0%

Other financials

Income statement

See full
Revenue$179.1M+10,055%
Operating income$168.9M+757%
Net income$169.7M+792%
EPS (diluted)$0.87+769%

Balance sheet

See full
Cash & equivalents$23.7M-36.1%
Total debt$631.0K-46.9%
Total equity$260.2M+229%
Total assets$277.2M+137%

Cash flow

See full
Operating cash flow-$8.1M+39.4%
CapEx--100%
Free cash flow-$4.7M+55.0%

Valuation

See full
Market cap$896.82M+42.4%
Enterprise value$873.75M+47.1%
P/E5.6×
P/S4.7×-36.1×

Profitability

See full
Operating margin81.7%+42.1pp
Net margin84%+43.4pp
FCF margin-281.5%-119pp

Returns & leverage

See full
Return on equity94.7%+65.1pp
Debt / equity0.0×
Current ratio54.3×+48.3×

Where this comes from

Reported directly by Arbutus Biopharma Corporation in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The source filing: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026.

Filed
May 13, 2026, 7:31 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001447028-26-000021
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Revenue$179,126$1,764
Less:
Imdusiran clinical development expense8912,171
AB-101-001 clinical development expense5261,899
Other research and development expense2,7034,889
General and administrative expense5,8895,832
Restructuring expense12,373
Other segment expense (1)237323

ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)

FAQ

What is Arbutus Biopharma Corporation's business segments — revenue?
Arbutus Biopharma Corporation (ABUS) reported business segments — revenue of $179.13M in Q1 2026.
How has Arbutus Biopharma Corporation's business segments — revenue changed year-over-year?
Arbutus Biopharma Corporation's business segments — revenue increased by 10054.5% year-over-year, from $1.76M to $179.13M.
What is the long-term trend for Arbutus Biopharma Corporation's business segments — revenue?
Over 2 years (2023 to 2025), Arbutus Biopharma Corporation's business segments — revenue has grown at a -11.9% compound annual growth rate (CAGR), from $18.14M to $14.08M.
What does business segments — revenue mean?
This represents the total gross income generated by the company's primary business segment through its core operations, including product sales, licensing agreements, and service contracts. It serves as a key indicator of the segment's market traction and ability to monetize its intellectual property or therapeutic assets.

Ask your AI about Arbutus Biopharma Corporation's business segments — revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude